Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials

Clinical Therapeutics

Volumn 32, Issue 14, 2010, Pages 2386-2397

  Wortmann, Robert L ^a   MacDonald, Patricia A ^b   Hunt, Barbara ^b   Jackson, Robert L ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Allopurinol; Colchicine; Febuxostat; Flares; Gout; Naproxen

Indexed keywords

ALLOPURINOL; COLCHICINE; FEBUXOSTAT; LANSOPRAZOLE; NAPROXEN; PLACEBO; URIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CORRELATION ANALYSIS; DIARRHEA; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL PAIN; GOUT; HEADACHE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOUTH INFECTION; NAUSEA; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TOOTH INFECTION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; THIAZOLES; TREATMENT OUTCOME; URIC ACID; YOUNG ADULT;

EID: 79951846844     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.008     Document Type: Article

References (38)

1. Zhang W., Doherty M., Bardin T., et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324. EULAR Standing Committee for International Clinical Studies Including Therapeutics.
2. Shoji A., Yamanaka H., Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004, 51:321-325.
3. Becker M.A., MacDonald P.A., Hunt B.J., et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 2008, 27:585-591.
4. Houpt J.B. The effect of allopurinol (HPP) in the treatment of gout. Arthritis Rheum 1965, 8:899-904.
5. Ogryzlo M.A., Harrison J. Evaluation of uricosuric agents in chronic gout. Ann Rheum Dis 1957, 16:425-437.
6. Wilson J.D., Simmonds H.A., North J.D. Allopurinol in the treatment of uraemic patients with gout. Ann Rheum Dis 1967, 26:136-142.
7. Yu T.F., Burns J.J., Gutman A.B. Results of a clinical trial of G-28315, a sulfoxide analog of phenylbutazone, as a uricosuric agent in gouty subjects. Arthritis Rheum 1958, 1:532-543.
8. Yue T.F., Gutman A.B. Effect of allopurinol (4-hydroxypyrazolo-(3,4-D)pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 1964, 37:885-898.
9. Becker M.A., Schumacher H.R., Wortmann R.L., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461.
10. Schumacher H.R., Becker M.A., Wortmann R.L., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008, 59:1540-1548.
11. Becker M.A., Schumacher H.R., Espinoza L.R., et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Res Ther 2010, 12:R63.
12. Schlesinger N. Management of acute and chronic gouty arthritis: Present state-of-the-art. Drugs 2004, 64:2399-2416.
13. Borstad G.C., Bryant L.R., Abel M.P., et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004, 31:2429-2432.
14. Paulus H.E., Schlosstein L.H., Godfrey R.G., et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974, 17:609-614.
15. Takano Y., Hase-Aoki K., Horiuchi H., et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005, 76:1835-1847.
16. Uloric [package insert] 2009, Takeda Pharmaceuticals America, Inc, Deerfield, Ill.
17. Becker M.A., Schumacher H.R., MacDonald P.A., et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009, 36:1273-1282.
18. Schumacher H.R., Becker M.A., Lloyd E., et al. Febuxostat in the treatment of gout: 5-Yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009, 48:188-194.
19. Wallace S.L., Robinson H., Masi A.T., et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20:895-900.
20. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
21. Robert S., Zarowitz B.J., Peterson E.L., Dumler F. Predictability of creatinine clearance estimates in critically ill patients. Crit Care Med 1993, 21:1487-1495.
22. Guidance for industry. Drug-induced liver injury: Premarketing clinical evaluation US Food and Drug Administration, Accessed September 22, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf.
23. Kippen I., Klinenberg J.R., Weinberger A., Wilcox W.R. Factors affecting urate solubility in vitro. Ann Rheum Dis 1974, 33:313-317.
24. Campion E.W., Glynn R.J., DeLabry L.O. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987, 82:421-426.
25. Zhang W., Doherty M., Pascual E., et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1301-1311. EULAR Standing Committee for International Clinical Studies Including Therapeutics.
26. Luk A.J., Simkin P.A. Epidemiology of hyperuricemia and gout. Am J Manag Care 2005, 11(Suppl):S435-S442.
27. Kuzell W., Glover R., Gibbs J., et al. Effect of anturane on serum uric acid and cholesterol in gout: A long-term study. Acta Rheumatol Scand Suppl 1964, 8:31-40.
28. Schlesinger N., Norquist J.M., Watson D.J. Serum urate during acute gout. J Rheumatol 2009, 36:1287-1289.
29. Perez-Ruiz F., Atxotegi J., Hernando I., et al. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: A prospective study. Arthritis Rheum 2006, 55:786-790.
30. Fam A.G. Treating acute gouty arthritis with selective COX 2 inhibitors. BMJ 2002, 325:980-981.
31. Pouliot M., James M.J., McColl S.R., et al. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998, 91:1769-1776.
32. Li E.K. Gout: A review of its aetiology and treatment. Hong Kong Med J 2004, 10:261-270.
33. Liu-Bryan R., Scott P., Sydlaske A., et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936-2946.
34. Martinon F., Pétrilli V., Mayor A., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
35. Emmerson B.T. The management of gout. N Engl J Med 1996, 334:445-451.
36. Wortmann R.L. Effective management of gout: An analogy. Am J Med 1998, 105:513-514.
37. Pascual E., Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007, 66:1056-1058.
38. Prevacid [package insert] 2008, Takeda Pharmaceuticals America, Inc, Deerfield, Ill.